Sanofi Invests $25 Million in China’s Adagene to Advance SAFEbody Program
French pharmaceutical major Sanofi (NASDAQ: SNY) is set to make a USD 25 million investment...
Cancer
Esteve to Acquire Sanofi’s Caprelsa Rights in Over 50 Countries for Medullary Thyroid Cancer Treatment
Spanish multinational pharmaceutical company Esteve, which also operates an industrial site in China, is set...
Huadong Medicine’s First-in-Class ADC HDM2012 Gains FDA Phase I Trial Clearance
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clearance from the...
HutchMed’s Orpathys Approved in China for EGFR-MET Co-Mutation NSCLC
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that it has received marketing approval from...
Astellas Pharma’s Vyloy Gains First Prescriptions Across China for Gastric Cancer
Japan-based Astellas Pharma Inc. (TYO: 4503) announced that the first prescriptions for Vyloy (zolbetuximab) in...
Avistone’s Vebreltinib Wins NMPA Approval for MET-Amplified NSCLC
Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd. announced that its subsidiary Pearl Bio’s c-MET inhibitor vebreltinib...
BMS Secures FDA Approval for Updated Labels of Breyanzi and Abecma
US major Bristol-Myers Squibb (BMS; NYSE: BMY) announced that the US Food and Drug Administration...
GenFleet Therapeutics Files for Hong Kong IPO Amid KRAS Inhibitor Success
China-based GenFleet Therapeutics (Shanghai) Inc. has submitted its initial public offering (IPO) application to the...
Mabwell Bioscience Partners With Calico Life Sciences on 9MW3811 Development
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) is set to enter into a licensing...
Sino Biopharmaceutical’s LM-108 Gains CDE BTD for Gastric Adenocarcinoma
Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has obtained Breakthrough Therapy Designation (BTD) from...
Mabwell Bioscience Grants Qilu Pharma Exclusive Rights to Mailisheng in Greater China
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced a licensing agreement with compatriot firm...
Fosun Pharma’s Serplulimab Approved for ES-SCLC in the UK and India
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai...
Bio-Thera Solutions Initiates Phase III Trial of BAT8006 for Platinum-Resistant Ovarian Cancer
Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced the successful first patient dosing in its Phase III...
EMA Panel Recommends Brukinsa Tablet Formulation for Approval
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
CARsgen’s Satri-cel NDA Accepted by China’s NMPA for Gastric Adenocarcinoma
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that the National Medical Products Administration (NMPA)...
Immvira Bioscience Files for Hong Kong IPO to Advance Oncolytic Immunotherapy Pipeline
Shenzhen-based Immvira Bioscience Inc. has filed for an initial public offering (IPO) with the Hong...
Henlius Biotech Doses First Patient in Japanese Bridging Trial of Serplulimab for ES-SCLC
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced the successful completion of first patient dosing...
BeOne Medicines Launches Ziihera for HER2-High Biliary Tract Cancer in China
China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced the official commercial availability...
Medilink Therapeutics’ YL201 Wins FDA Breakthrough Therapy Designation for SCLC
Suzhou-based Medilink Therapeutics announced that it has received Breakthrough Therapy Designation (BTD) from the US...
FDA Approves AstraZeneca’s Datopotamab deruxtecan for EGFR-Mutated NSCLC
The US Food and Drug Administration (FDA) this week approved Datopotamab deruxtecan (Dato-DXd), a TROP-2-targeted...